Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
15 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-K/A
2021 FY
Annual report (amended)
27 Jun 22
10-K/A
2021 FY
Annual report (amended)
17 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
7 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Feb 24
8-K/A
Report of Independent Registered Public Accounting Firm
8 Dec 23
8-K
Entry into a Material Definitive Agreement
5 Oct 23
8-K
Panacea Life Sciences Holdings, Inc. Continues Growth Trajectory with Acquisition of the PÜR LIFE Medical Franchise
2 Oct 23
8-K
Entry into a Material Definitive Agreement
10 Jul 23
8-K
Departure of Directors or Certain Officers
2 Jun 23
8-K
Entry into a Material Definitive Agreement
14 Feb 23
8-K
Other Events
23 Jan 23
8-K
Entry into a Material Definitive Agreement
23 Dec 22
Registration and prospectus
D
$5M in equity / options
18 Feb 21
S-1
IPO registration
31 Dec 19
D
$25M in equity
12 Apr 19
RW
Registration withdrawal request
15 Mar 19
D
$3.6M in equity, sold $1.15M, 10 investors
22 Feb 19
D
$1M in equity, sold $641.59K, 7 investors
29 Jan 19
S-8
Registration of securities for employees
26 Dec 18
S-1
IPO registration
11 Sep 17
8-A12G
Registration of securities
21 Aug 17
8-A12B
Registration of securities on exchange
18 Aug 17
Other
UPLOAD
Letter from SEC
8 Jul 22
CORRESP
Correspondence with SEC
27 Jun 22
UPLOAD
Letter from SEC
27 May 22
CORRESP
Correspondence with SEC
17 May 22
UPLOAD
Letter from SEC
5 May 22
SEC STAFF ACTION
SEC staff action: Order
25 Apr 22
CT ORDER
Confidential treatment order
23 Sep 16
EFFECT
Notice of effectiveness
1 Jul 15
CORRESP
Correspondence with SEC
29 Jun 15
CORRESP
Correspondence with SEC
19 Jun 15